Dr. Ahad Ali Sadiq, MD

Dr. Sadiq practices at American Oncology Partners PA in Asheville, North Carolina.

Dr. Sadiq's NPI, 1861525560, was assigned on March 13, 2007. Dr. Sadiq holds Indiana license 01072351A.

Dr. Sadiq's primary practice is American Oncology Partners PA, at 551 Brevard Rd, Asheville, NC 28806 in Buncombe County. The practice phone is (614) 383-6000.

Dr. Sadiq's primary practice is American Oncology Partners PA in Asheville, North Carolina. Dr. Sadiq is also affiliated with Parkview Regional Medical Center. The medical group on file is Zangmeister Cancer Center. Dmand AI also links Dr. Sadiq to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sadiq practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sadiq's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Sadiq's licenses on file in 3 states: Indiana, Minnesota and Texas.

CMS data shows 54,450 Medicare services from Dr. Sadiq across 44 procedure codes in 2024, for 569 Medicare patients. Medicare paid $872,391 for them. Every service was in an office.

CMS counts 569 Medicare patients who saw Dr. Sadiq in 2024. The largest group is 65 to 74, with 279 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sadiq's median patient age at 72, with 52% women.

In 2024, Dr. Sadiq wrote 1,133 Medicare Part D claims for 224 patients. 70% of them were for generic drugs. CMS names the drug for 841 of them, across 28 drugs with 11 or more claims each, at $1,594,152 in total drug cost. In 2023, CMS named 773 claims across 31 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Sadiq for performance year 2024, reported as part of a group. Dr. Sadiq accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Sadiq, published from 2011 to 2019. 2013 was the busiest year, with 2. The most frequent topics are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Antineoplastic Agents. Dr. Sadiq's most frequent co-authors are Robert Arthur Kratzke, MD, Manish R. Patel, DO and Andrea L. Amico.

Dmand AI links Dr. Sadiq to 5 clinical trials, 2 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms and Leukemia, Lymphocytic, Chronic, B-Cell. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Sadiq that name 2 trials.

CMS Open Payments shows 481 general payments to Dr. Sadiq from 48 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Bristol-Myers Squibb Company paid the most, $349,136. It also lists 4 research payments totaling $6,131 from 2017 to 2025, naming 2 clinical trials.